Lexicon Pharmaceuticals (LXRX) will get an upfront payment of $25 million from Viatris (VTRS) for an exclusive license to commercialize sotagliflozin outside of the US and Europe in all indications.
Sotagliflozin is a medication used to reduce the risk of death and hospitalization in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. The drug was approved the US Food and Drug Administration in May 2023, Lexicon said Wednesday in a statement.
Under the licensing accord, Lexicon is eligible for potential regulatory and sales milestone payments as well as tiered royalties on annual net sales.
Lexicon holds sole commercialization rights for the drug in the US and Europe. The company will provide clinical and commercial supply of sotagliflozin to Viatris at a transfer price.
Shares of Lexicon fell 1% in recent after-hours activity, and Viatris dropped 0.2% in the regular session.
Price: 1.8900, Change: -0.02, Percent Change: -1.05
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。